About

Patients' waiting time at ERs is a ticking bomb for both patients’ health and hospitals’ budget. Just 1 hour of waiting inside an ER can increase 30 % the cost care while based on waiting time metrics, NHS ERs have 5 times worst efficiency compering to ten years ago creating a 4b euros/year problem just in the UK.

Solution & Product

EMMA is a Clinical Decision Support System that assists ER personnel to triage and monitor incoming patients. Wearable biosensors detect any heath deterioration and timely notifications are sent to the mobile app of ER personnel to provide the exact location and severity of patients and continious prognosis of patients outcomes. Also, EMMA creates a probabilistic framework to inform healthcare professionals on the prediction estimates (in the form of probabilities) of a patient to be admitted in the hospital or discharged and furthermore when hospitalized if there is a high chance to be admitted in the ICU. This patient stratification algorithm especially in medium-risk incidents, may save lives and result to better patient outcomes in the long run. In addition, the calculated estimation of the potential duration of hospitalization allows for more efficient hospital resource management.

Innovation & Scalability

The fact that our technology exploits edge computing establishes a significant advantage against current state-of-the-art solutions. It realizes a more feasible and sustainable business case, avoiding the huge costs, connection dependence and complexity that cloud infrastructures demand, while ensures data privacy which is the biggest barrier when dealing with medical data. EMMA is co-designed with our users and future clients who identified the clinical need, involved in the design and development processes and are actively testing it in real-life clinical context. Also, EMMA has a solid advantage against potential competition since we are using edge computing, it means that we are keeping data and their analysis locally at the physical area of Hospitals. Industrialization phase: currently on going until end of 2023 Solid traction and Business development: Q2 2024 Certification: Q3, 2024 Full commercial deployment: Q3, 2025

Traction & achievements

The prototype developments of EMMA succeeded to receive so far 635.000€ in research grants and Vidavo S.A. invested another 250K€. EMMA is currently tested in two EDs in University Hospitals in Thessaloniki, Greece. Results from our first pilot were presented at IEEE Globecom Workshop in Taipei, Taiwan, in December 2020 . EMMA is a patent-pending technology submitted in April 2021 in European Patent Office. Additionally, EMMA was selected from Health Founders accelerator in Tallin, Estonia for a 9-month mentoring program focusing on sales and business development. Recently, our technology was selected from Santa Clara University, CA for a 5-month mentorship program aiming to enhance the AI perspective of EMMA. Finally, EMMA is part of EIT Health Innostars Awards 2022 program, proving the business potential and acknowledgement on the Healthcare industry.

Team & Why Us

EMMA is created by the joint vision of VIDAVO, the biggest telemedicine company in Greece and the Lab of Medical Physics and Digital Innovation, School of Medicine, Aristotle University of Thessaloniki. EMMA’s CEO is Alexis Fourlis, an Electrical Engineer with 8 years’ experience in designing and building medical IoT devices and managing projects in terms of hardware and firmware development, resources, and budget. He was a researcher scholar at Santa Clara University, CA in Silicon Valley, where EMMA’s machine learning perspective was enriched. EMMA’s CSO is Dr. Antonis Billis, an Electrical Engineer, holds a PhD in Medical Informatics and more specifically AI-driven clinical decisions support systems and digital biomarkers. He has great experience as scientific coordinator of multiple EU funded research projects related to digital health, including development of AI services in smart hospitals and quality of life support of cancer survivors using AI and Big Data.

Funding Needs

Contact us for more information about this aspect.